3-(2-chlorophenyl)-5-methyl-1,2,4-oxadiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(2-chlorophenyl)-5-methyl-1,2,4-oxadiazole
• 化学式: C₉H₇ClN₂O
• 分子量: 194.62
• InChiKey: SHRWQRGLJVOSNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  邻氯苯腈 在 盐酸羟胺 、 sodium carbonate 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 3-(2-chlorophenyl)-5-methyl-1,2,4-oxadiazole
  参考文献：
  名称：

  通过Rh（III）催化恶二唑与烯丙醇级联反应合成功能化的茚衍生物

  摘要：

  通过CH活化/分子内羟醛缩合反应已实现了新型功能化茚衍生物的高效铑（III）催化合成。该级联反应是一种原子经济的方案，可以进一步应用于构建更复杂的化合物。

  DOI：

  10.1002/adsc.201801606

文献信息

• [EN] AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'AMIDE D'AZÉTIDINE EN TANT QU'ANTAGONISTES DES RÉCEPTEURS D'ORÉXINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014141065A1

  公开（公告）日：2014-09-18

  The present invention relates to azetidine amide derivatives derivatives of formula (I) wherein rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及式(I)的吡嗪酰胺衍生物衍生物，其中环A1、A2和A3如描述中所述，其药学上可接受的盐，其制备方法，含有一种或多种式(I)化合物的药物组合物，以及它们作为药物的用途，特别是它们作为促进睡眠的药物。
• Phosphodiesterase Inhibitors
  申请人：Palle P. Venkata

  公开号：US20070259874A1

  公开（公告）日：2007-11-08

  The present invention relates to isoxazoline derivatives and their analogues, which can be used as phosphodiesterase (PDE) type IV selective inhibitors. Compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases, especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and their use as PDE type IV selective inhibitors, are provided.

  本发明涉及异噁唑啉衍生物及其类似物，可用作磷酸二酯酶（PDE）IV型选择性抑制剂。本文所披露的化合物可用于治疗艾滋病、哮喘、关节炎、支气管炎、慢性阻塞性肺疾病（COPD）、银屑病、过敏性鼻炎、休克、特应性皮炎、克罗恩病、成人呼吸窘迫综合症（ARDS）、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎、溃疡性结肠炎和其他炎症性疾病，尤其是在人类中。本文提供了所披露的化合物的制备方法、含有所披露的化合物的药物组合物以及它们作为PDE IV型选择性抑制剂的用途。
• OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20150252032A1

  公开（公告）日：2015-09-10

  The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives of formula (I) wherein R, and the rings A 1 A 2 and A 3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）的[ortho bi-（hetero-）aryl]-[2-（meta bi-（hetero-）aryl）-pyrrolidin-1-yl]-methanone衍生物，其中R和环A1A2和A3如描述中所述，以及其药学上可接受的盐、其制备方法、含有一个或多个公式（I）化合物的制药组合物以及它们作为药物的用途，特别是作为促进睡眠激素受体拮抗剂的用途。
• AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20160024064A1

  公开（公告）日：2016-01-28

  The present invention relates to azetidine amide derivatives derivatives of formula (I) wherein rings A 1 A 2 and A 3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及一种式（I）的氮杂环酰胺衍生物，其中环A1、A2和A3如说明书所述，其药学上可接受的盐，其制备方法，包含一种或多种式（I）化合物的制药组合物，以及它们作为药物的用途，特别是作为促进睡眠的药物，尤其是作为促进睡眠的药物。
• Compounds, compositions and methods of treatment for heart failure
  申请人：Cytokinetics, Inc.

  公开号：EP2397462A2

  公开（公告）日：2011-12-21

  Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

  某些取代的脲衍生物可选择性地调节心肌肌节，例如通过增强心肌肌球蛋白的作用，可用于治疗收缩性心力衰竭，包括充血性心力衰竭。